Phase II Study Shows New Drug is Effective against NSCLC | Lung Cancer Dispatch |

Preliminary results from an ongoing phase II clinical trial of new lung cancer drug AXL1717 suggest that the drug is effective against non-small cell lung cancer (NSCLC). Patients with advanced NSCLC received either AXL1717 or chemotherapy with docetaxel (Taxotere) as a second-line treatment. AXL1717, which acts by inhibiting a protein called IGF1R, appeared to be as effective as Taxotere at delaying cancer progression. AXL1717 may be a treatment option for patients who do not respond or become resistant to Taxotere or other second-line treatments. AXL1717 is manufactured by drug company Axelar. More information about the clinical trial can be found here: